DAVPX
Price
$36.26
Change
-$1.10 (-2.94%)
Updated
Dec 18 closing price
GFACX
Price
$64.14
Change
-$8.99 (-12.29%)
Updated
Dec 18 closing price
Ad is loading...

DAVPX vs GFACX

Header iconDAVPX vs GFACX Comparison
Open Charts DAVPX vs GFACXBanner chart's image
Davenport Core Leaders Fund
Price$36.26
Change-$1.10 (-2.94%)
VolumeN/A
CapitalizationN/A
American Funds Growth Fund of Amer C
Price$64.14
Change-$8.99 (-12.29%)
VolumeN/A
CapitalizationN/A
DAVPX vs GFACX Comparison Chart
Loading...
View a ticker or compare two or three
VS
DAVPX vs. GFACX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DAVPX is a Buy and GFACX is a Buy.

FUNDAMENTALS
Fundamentals
GFACX has more cash in the bank: 313B vs. DAVPX (1.13B). DAVPX pays higher dividends than GFACX: DAVPX (0.28) vs GFACX (0.00). DAVPX was incepted earlier than GFACX: DAVPX (27 years) vs GFACX (24 years). GFACX is a more actively managed with annual turnover of: 31.00 vs. DAVPX (19.00). GFACX has a lower initial minimum investment than DAVPX: GFACX (250) vs DAVPX (5000). GFACX annual gain was more profitable for investors over the last year : 34.28 vs. DAVPX (19.38). GFACX return over 5 years is better than : 47.11 vs. DAVPX (41.11).
DAVPXGFACXDAVPX / GFACX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence27 years24 years-
Gain YTD18.41832.96456%
Front LoadN/AN/A-
Min. Initial Investment50002502,000%
Min. Initial Investment IRAN/AN/A-
Net Assets1.13B313B0%
Annual Yield % from dividends0.280.00-
Returns for 1 year19.3834.2857%
Returns for 3 years13.0714.7189%
Returns for 5 years41.1147.1187%
Returns for 10 years97.6679.77122%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TIVC0.230.01
+3.77%
Tivic Health Systems
THRD11.350.23
+2.07%
Third Harmonic Bio
VRNT29.420.36
+1.24%
Verint Systems
PEN247.550.31
+0.13%
Penumbra
CNTX1.29-0.07
-5.15%
Context Therapeutics